Celldex Therapeutics (NASDAQ:CLDX) Sets New 12-Month Low – Here’s Why

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) reached a new 52-week low on Thursday . The stock traded as low as $20.91 and last traded at $22.26, with a volume of 920471 shares. The stock had previously closed at $21.91.

Analysts Set New Price Targets

CLDX has been the subject of a number of research analyst reports. HC Wainwright reissued a “buy” rating and issued a $80.00 target price on shares of Celldex Therapeutics in a research note on Thursday, December 19th. Cantor Fitzgerald reiterated an “overweight” rating and issued a $67.00 price objective on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $62.25.

Celldex Therapeutics Trading Up 1.6 %

The firm has a 50-day moving average price of $24.93 and a two-hundred day moving average price of $30.08.

Hedge Funds Weigh In On Celldex Therapeutics

Hedge funds have recently made changes to their positions in the business. EverSource Wealth Advisors LLC lifted its position in shares of Celldex Therapeutics by 215.7% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,285 shares of the biopharmaceutical company’s stock worth $32,000 after purchasing an additional 878 shares in the last quarter. KBC Group NV increased its stake in Celldex Therapeutics by 31.2% in the 3rd quarter. KBC Group NV now owns 2,081 shares of the biopharmaceutical company’s stock valued at $71,000 after buying an additional 495 shares during the last quarter. Headlands Technologies LLC bought a new stake in Celldex Therapeutics during the 4th quarter worth about $81,000. AlphaQuest LLC boosted its stake in shares of Celldex Therapeutics by 171.0% during the 4th quarter. AlphaQuest LLC now owns 4,287 shares of the biopharmaceutical company’s stock worth $108,000 after buying an additional 2,705 shares during the last quarter. Finally, E Fund Management Co. Ltd. bought a new position in shares of Celldex Therapeutics in the 4th quarter valued at about $273,000.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.